Table 3.

Statistical analysis of pharmacokinetic parameter estimates of abacavir for escalating doses administered under fasting conditionsa

ParameterAbacavir dose (mg)Comparisons of the following dose (mg) with 300-mg dose:
1003006009001,2001006009001,200
AUC0–∞ (μg · h/ml)
 LSM0.824.9313.5 21.7  29.0 
 95% CI0.60–1.133.56–6.839.70–18.815.6–30.320.8–40.4
 Mean ratiob 0.501.371.471.47
 90% CI0.43–0.581.18–1.601.26–1.711.26–1.71
C max (μg/ml)
 LSM0.492.39 4.36  7.48 8.85
 95% CI0.37–0.651.79–3.203.23–5.875.55–10.16.57–11.9
 Mean ratiob 0.620.911.040.92
 90% CI0.52–0.740.75–1.100.86–1.260.77–1.11
T max (h)c
 Median1.001.00 1.49  1.53 1.51
 Range0.63–2.500.73–1.500.75–3.021.00–2.651.00–2.00
 Mean difference0.130.730.530.57
 90% CI−0.28–0.58−0.01–1.380.02–1.210.13–0.98
t1/2β (h)
 LSM0.851.17 1.66  1.67 1.64
 95% CI0.75–0.971.02–1.351.43–1.921.44–1.941.42–1.91
 Mean ratio0.731.421.431.40
 90% CI0.64–0.821.24–1.621.25–1.631.23–1.60
  • a Results determined from analysis of variance.

  • b Geometric LSM ratios were calculated on the basis of estimates that were dose normalized to 100 mg.

  • c Untransformed data.